{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8"}]}],"title":"0 - 6 Months, n = 2067"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3"}]}],"title":"6 - 12 Months, n = 2041"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6"}]}],"title":"12 - 18 Months, n = 1944"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3"}]}],"title":"18 - 24 Months, n = 1832"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2"}]}],"title":"24 - 30 Months, n = 1753"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9"}]}],"title":"30 - 36 Months, n = 1677"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3"}]}],"title":"36 - 42 Months, n = 1620"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.4"}]}],"title":"42 - 48 Months, n = 1568"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6"}]}],"title":"48 - 54 Months, n = 1516"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1"}]}],"title":"54 - 60 Months, n = 1475"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2"}]}],"title":"60 - 66 Months, n = 1423"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4"}]}],"title":"66 - 72 Months, n = 1342"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7"}]}],"title":"72 - 78 Months, n = 788"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6"}]}],"title":"78 - 84 Months, n = 62"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.4"}]}],"title":"84 - 90 Months, n = 34"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0"}]}],"title":"90 - 96 Months, n = 10"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"96 - 102 Months, n = 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"Concomitant therapy with oral corticosteroids (up 5 to 10 mg daily prednisone or equivalent) was permitted in the study. Reduction of oral corticosteroids was permitted, but not required, if a patient achieved at least a 50% improvement from baseline in both tender joint count and swollen joint count.\n\nThe data are reported for each 6-month period of the study where a month = 28 days. The last 6-month period is for months 96 through 101. The actually study duration in 28-day months was 98.85 months.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study.","timeFrame":"Baseline to the end of the study (up to 7 years, 7 months)","title":"Percentage of Participants With Concomitant Oral Corticosteroid Therapy","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}